Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 3,574,748 shares traded hands during trading, a decline of 38% from the previous session’s volume of 5,797,532 shares.The stock last traded at $127.07 and had previously closed at $127.19.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on ITCI shares. Needham & Company LLC reissued a “hold” rating and set a $100.00 price objective on shares of Intra-Cellular Therapies in a research report on Monday. Morgan Stanley lifted their price target on Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. JPMorgan Chase & Co. lifted their price target on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 price target on shares of Intra-Cellular Therapies in a research report on Monday, September 16th. Finally, Royal Bank of Canada lifted their price objective on Intra-Cellular Therapies from $106.00 to $108.00 and gave the stock an “outperform” rating in a report on Friday, October 4th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $97.23.
View Our Latest Analysis on ITCI
Intra-Cellular Therapies Trading Down 0.1 %
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The company had revenue of $175.40 million for the quarter, compared to analysts’ expectations of $172.30 million. During the same period in the previous year, the firm earned ($0.25) earnings per share. The firm’s quarterly revenue was up 39.0% on a year-over-year basis. As a group, sell-side analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.
Insider Activity
In related news, President Michael Halstead sold 22,869 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total value of $2,038,085.28. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Sharon Mates sold 51,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $91,834,228.20. This trade represents a 4.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.60% of the company’s stock.
Institutional Trading of Intra-Cellular Therapies
A number of institutional investors have recently bought and sold shares of the stock. True Wealth Design LLC purchased a new stake in Intra-Cellular Therapies in the third quarter worth $32,000. GAMMA Investing LLC boosted its holdings in Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 240 shares in the last quarter. Capital Performance Advisors LLP acquired a new stake in Intra-Cellular Therapies in the third quarter worth about $74,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Intra-Cellular Therapies during the third quarter worth about $97,000. Finally, Quarry LP lifted its holdings in shares of Intra-Cellular Therapies by 260.0% during the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 1,300 shares during the period. 92.33% of the stock is currently owned by institutional investors.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
See Also
- Five stocks we like better than Intra-Cellular Therapies
- What is the NASDAQ Stock Exchange?
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Stock Market Sectors: What Are They and How Many Are There?
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.